Asklepios BioPharmaceutical, Inc. (AskBio)’s Post

The #AskBio team recently returned from the #IAPRD2024 World Congress in Lisbon. While on site, we engaged with various experts from the movement disorder community. Our experience was capped off by a packed house for an oral presentation by our VP of Global Clinical Development, Amber Van Laar, who delivered 18-month PD safety, preliminary efficacy, and imaging data for our Phase 1b clinical trial for AB-1005, an investigational #genetherapy for treating patients with Parkinson’s disease. (For more information about the AB-1005 Phase 1b Trial, visit clinicaltrials.gov (NCT#04167540). #Parkinsonsdisease

  • No alternative text description for this image
  • No alternative text description for this image
Luis Quintino

Creating Effective Therapies for Chronic Incurable Diseases

2mo

Amazing data and the culmination of decades of failing up. Sincere Congratulations

Like
Reply
Cynthia Wagner

Medical Science Liaison with therapeutic expertise in Oncology | Neuroscience | Rare Disease | Gastroenterology

2mo

Exciting news for patients with Parkinson's Disease! Congratulations!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics